Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes.
about
Interventions for smoking cessation and reduction in individuals with schizophreniaInterventions for smoking cessation and reduction in individuals with schizophreniaA Nicotine Challenge to the Self-Medication Hypothesis in a Neurodevelopmental Animal Model of SchizophreniaPrevalence, severity, and co-occurrence of chronic physical health problems of persons with serious mental illnessEmployment and the associated impact on quality of life in people diagnosed with schizophreniaFifty psychological and psychiatric terms to avoid: a list of inaccurate, misleading, misused, ambiguous, and logically confused words and phrasesAre executive function and impulsivity antipodes? A conceptual reconstruction with special reference to addictionA neurobiological basis for substance abuse comorbidity in schizophreniaA unified framework for addiction: vulnerabilities in the decision processManagement of "dual diagnosis" patients : consensus, controversies and considerationsHomers regulate drug-induced neuroplasticity: implications for addictionA randomized study of contingency management in cocaine-dependent patients with severe and persistent mental health disordersAnalysis of West Virginia medicaid claims data for the prevalence of medical conditions and use of drugs likely to cause QT prolongation in patients with schizophrenia.Huntington disease as a dual diagnosis disorder: data from the National Research Roster for Huntington disease patients and families.The association of psychiatric comorbidity and use of the emergency department among persons with substance use disorders: an observational cohort study.Unmet need for mental health care in schizophrenia: an overview of literature and new data from a first-admission study.Fundamental Causes of Housing Loss among Persons Diagnosed with Serious and Persistent Mental Illness: A Theoretically Guided Test.Neurocognitive functioning of individuals with schizophrenia: using and not using drugs.Ethanol sensitization in a neurodevelopmental lesion model of schizophrenia in ratsNeonatal amygdala lesions: co-occurring impact on social/fear-related behavior and cocaine sensitization in adult rats.Treatment outcome in patients receiving assertive community treatmentMotivational responses to natural and drug rewards in rats with neonatal ventral hippocampal lesions: an animal model of dual diagnosis schizophreniaComorbid mood, psychosis, and marijuana abuse disorders: a theoretical reviewOverview and initial validation of two detailed, multidimensional, retrospective measures of substance use: the Lifetime Substance Use Recall (LSUR) and Longitudinal Substance Use Recall for 12 Weeks (LSUR-12) Instruments.Duration of assertive community treatment and the interpretation of routine outcome data.Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis.Developmental pathology, dopamine, stress and schizophrenia.Changes in individual needs for care and quality of life in Assertive Community Treatment patients: an observational study.A case-linkage study of crime victimisation in schizophrenia-spectrum disorders over a period of deinstitutionalisation.Impulsivity and sensation seeking in alcohol abusing patients with schizophrenia.Advisor-Teller Money Manager (ATM) therapy for substance use disorders.The association between cannabis abuse and subsequent schizophrenia: a Swedish national co-relative control studyThe 'check effect' reconsidered.An Integrated Approach for Dually Diagnosed Patients in a Substance Abuse Treatment Program: Case Presentation.Dual recovery among people with serious mental illnesses and substance problems: a qualitative analysisSubstance abuse in patients with schizophrenia.Schizophrenia: a systemic disorderA novel SNP in COMT is associated with alcohol dependence but not opiate or nicotine dependence: a case control studyDifferences in substance-related risk behavior between dual and triple diagnosed severely mentally ill adultsDSM-IV schizotypal personality disorder: a taxometric analysis among individuals with and without substance use disorders in the general population
P2860
Q24235017-2C268C47-C9F1-4B36-8DAF-51DA967C83FDQ24242470-3FCA6FEB-9128-487F-9052-D25048715D21Q24634186-7CED2C43-0EBF-410C-8512-7BB3017ACBB6Q24655050-5E9ADB67-F98F-4522-A2A2-D3C0E9D1642BQ26796439-978C7F52-AF78-406E-B6A4-BC975FC290EAQ26797367-84B08FB3-4DFD-48B6-825D-0253BF24E2ACQ26824038-4A1E29D7-0A1B-4803-919A-AC7C076D46CFQ28347063-76EB5057-72D6-42E7-B9BB-CC9FE30226DDQ28680729-33A38644-5621-4FEC-9FDF-AF8DA18CFFC7Q30400782-A789BAAD-3AAD-4706-BA0E-043D82170939Q30491852-7E61BBED-F323-4433-81FC-26D4606A81A8Q30537387-B5FA0051-ECF0-4576-B426-A94FFEB17027Q30832167-5C04F5CC-2213-4F22-B2DA-4E7118C9BF03Q33255155-F7B4F9A3-4A1C-4A51-98E9-4E950365564DQ33389538-5F965C62-C1B2-4F63-9D52-B282A494B933Q33464064-EAEB85A0-3603-46A5-B6A1-5001574E09DBQ33638081-82DD2D03-D69B-485E-8DF7-FA67E202073CQ33762494-6437E8EB-681A-49F2-B977-DE7CBC0DE058Q33935945-759FE89E-A2A4-449C-956F-C054E2BC8725Q33956965-23F78D8B-E9AC-4F74-9246-71B6C4181601Q34023618-A760F275-A00C-4980-A742-ACC94633DB40Q34056092-C7A544C3-3BD3-4630-BD49-4E73C885CCBDQ34067376-1CFC54E3-DE3A-4E4C-A875-519A77C05395Q34077614-E4E1ED49-239A-4055-9084-6CA090A0EFC2Q34185092-47E2FC36-0293-4B64-B8DC-06CD418F8405Q34235419-0CFDC3E5-4664-4228-A51C-2EA57491FD01Q34500539-AD3E9057-882A-4BBE-A1C8-BE2AA7106FC1Q34539451-4AC13E57-C33A-47EA-8178-C3377007AAC9Q34593373-E476150A-E40E-43F0-9651-DD19C35E635DQ34689535-78AE2456-65A0-4EF8-8B28-7818D7AC5FD9Q34718546-3370FAF0-7076-494B-A0A8-BACF0647B65DQ34809059-6F82C059-E700-40BB-A958-123A242EB7FDQ34981279-1CBE4D58-4F50-439F-AC6C-4AE426D898F6Q35017215-A27554FD-A341-4395-BB50-2FBBEAFCD2BAQ35079480-ECE70A9F-0207-4652-A644-4D7546721BBCQ35236689-62913D72-ED58-4171-B45B-FBA2133DCCF1Q35323907-BB2A17BF-1DF4-4940-BCE1-F5A954563146Q35712064-6D49F0E0-F2D1-4440-81E2-7C977C331642Q35944189-B248FE12-9C18-4025-880F-A20589EF2110Q35994995-8C29D363-F8E0-4B44-9679-8235348F7280
P2860
Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes.
description
1999 nî lūn-bûn
@nan
1999 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մարտին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes.
@ast
Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes.
@en
Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes.
@nl
type
label
Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes.
@ast
Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes.
@en
Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes.
@nl
prefLabel
Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes.
@ast
Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes.
@en
Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes.
@nl
P1476
Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes.
@en
P2093
P304
P356
10.1016/S0920-9964(98)00161-3
P407
P478
P577
1999-03-01T00:00:00Z